

CITATION REPORT

List of articles citing

Efficacy and safety of an extended-release niacin (Niaspan): a long-term study

DOI: 10.1016/s0002-9149(98)00731-0

American Journal of Cardiology, 1998, 82, 74U-81U; discussion 85U-86U.

Source: <https://exaly.com/paper-pdf/28951583/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| # | Paper | IF | Citations |
|-----|--|----|-----------|
| 209 | New developments in the treatment of low high-density lipoprotein cholesterol. 1999 , 1, 24-30 | | 2 |
| 208 | Combination drug therapy for combined hyperlipidemia. 1999 , 1, 244-50 | | 16 |
| 207 | Lipid-altering drugs in development. 1999 , 1, 463-9 | | 2 |
| 206 | Vitamins. 2000 , 23, 418-426 | | |
| 205 | Raising high-density lipoprotein cholesterol with niacin and fibrates: a comparative review. <i>American Journal of Cardiology</i> , 2000 , 86, 46L-50L | 3 | 188 |
| 204 | Niacin dosing: relationship to benefits and adverse effects. 2000 , 2, 64-71 | | 69 |
| 203 | The antilipidemic effects of plain and extended-release niacin. 2000 , 3, 131-135 | | 3 |
| 202 | Current perspectives on the management of hypertriglyceridemia. 2000 , 140, 232-40 | | 37 |
| 201 | Current, new and future treatments in dyslipidaemia and atherosclerosis. 2000 , 60, 55-93 | | 53 |
| 200 | The evolving role of high-density lipoprotein in reducing cardiovascular risk. 2001 , 4, 65-72 | | 2 |
| 199 | The benefits of niacin in atherosclerosis. 2001 , 3, 74-82 | | 81 |
| 198 | Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia. <i>American Journal of Cardiology</i> , 2001 , 87, 476-9, A7 | 3 | 81 |
| 197 | A Review of Niaspan, an Extended-Release Niacin. 2001 , 4, 250-255 | | 5 |
| 196 | Cholesterol and glycemic effects of Niaspan in patients with type 2 diabetes. 2001 , 21, 1473-8 | | 21 |
| 195 | Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. 2002 , 162, 1568-76 | | 432 |
| 194 | Niacin (nicotinic acid) in non-physiological doses causes hyperhomocysteinaemia in Sprague-Dawley rats. 2002 , 87, 115-9 | | 19 |
| 193 | Beyond LDL-C--the importance of raising HDL-C. 2002 , 18, 36-44 | | 33 |

| | | | |
|-----|--|---|-----|
| 192 | New advances in lipid-modifying therapies for reducing cardiovascular risk. 2002 , 97, 59-66 | | 21 |
| 191 | Modification of high-density lipoprotein cholesterol in the management of cardiovascular risk. 2002 , 22, 1266-77 | | 4 |
| 190 | High-density lipoproteins and atherosclerosis. <i>American Journal of Cardiology</i> , 2002 , 90, 62i-70i | 3 | 96 |
| 189 | Future directions in lipid therapies. 2002 , 19, 61-72 | | 5 |
| 188 | Toxicity of antilipidemic agents: facts and fictions. 2003 , 5, 403-10 | | 1 |
| 187 | Niacin: a powerful adjunct to other lipid-lowering drugs in reducing plaque progression and acute coronary events. 2003 , 5, 418-22 | | 8 |
| 186 | Niacin, lipids, and heart disease. 2003 , 5, 470-6 | | 42 |
| 185 | Effects of nonstatin lipid drug therapy on high-density lipoprotein metabolism. <i>American Journal of Cardiology</i> , 2003 , 91, 18E-23E | 3 | 83 |
| 184 | Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADVICOR Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). <i>American Journal of Cardiology</i> , 2003 , 91, 667-72 | 3 | 133 |
| 183 | Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels. <i>American Journal of Cardiology</i> , 2003 , 91, 1304-10 | 3 | 65 |
| 182 | Regulation of reverse cholesterol transport and clinical implications. <i>American Journal of Cardiology</i> , 2003 , 92, 42J-49J | 3 | 146 |
| 181 | The rhinological side-effects of systemic drugs. 2003 , 28, 381-5 | | 7 |
| 180 | Management of selected lipid abnormalities: hypertriglyceridemia, isolated low HDL-cholesterol, lipoprotein(a), and lipid abnormalities in renal diseases and following solid organ transplantation. 2003 , 21, 377-92 | | 6 |
| 179 | Niacin-ER and lovastatin treatment of hypercholesterolemia and mixed dyslipidemia. 2003 , 37, 106-15 | | 10 |
| 178 | Varying cost and free nicotinic acid content in over-the-counter niacin preparations for dyslipidemia. 2003 , 139, 996-1002 | | 57 |
| 177 | Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapy. 2004 , 39, 419-25 | | 60 |
| 176 | Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. 2004 , 110, 3512-7 | | 788 |
| 175 | The metabolic syndrome: pathophysiology, clinical relevance, and use of niacin. 2004 , 38, 277-85 | | 11 |

| | | | |
|-----|---|---|-----|
| 174 | Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells. 2004 , 45, 1835-45 | | 167 |
| 173 | Comparative effects of lipid-lowering therapies. 2004 , 47, 73-104 | | 83 |
| 172 | Safety and compliance with once-daily niacin extended-release/lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) study. <i>American Journal of Cardiology</i> , 2004 , 94, 306-11 | 3 | 40 |
| 171 | Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. 2004 , 255, 188-205 | | 260 |
| 170 | Management of the metabolic syndrome-nicotinic acid. 2004 , 33, 557-75, vii | | 22 |
| 169 | Optimal management of hyperlipidemia in primary prevention of cardiovascular disease. 2004 , 97, 355-66 | | 20 |
| 168 | Niaspan [®] : creating a new concept for raising HDL-cholesterol. 2005 , 7, F41-F47 | | 12 |
| 167 | Combination of dietary phytosterols plus niacin or fenofibrate: effects on lipid profile and atherosclerosis in apo E-KO mice. 2005 , 16, 222-8 | | 25 |
| 166 | Molasses increases HDL cholesterol in rats research note. 2005 , 75, 211-7 | | 2 |
| 165 | Modern intervention strategies for managing dyslipidaemia: the case for combination therapy. 2005 , 5, S17-S23 | | |
| 164 | The management of hyperlipidaemia. 2005 , 16, 382-387 | | |
| 163 | Reply to Al-Shaer, is atorvastatin more appropriate to use in combination with niacin than simvastatin in patients with the metabolic syndrome? (<i>Am Heart J</i> 2005;149:e17.). 2005 , 150, e7 | | |
| 162 | Prolonged-release nicotinic acid: a review of its use in the treatment of dyslipidaemia. 2005 , 65, 2719-40 | | 73 |
| 161 | Combination of fenofibrate plus low-dose nicotinic acid added to statin treatment in type 2 diabetes: An open-label, crossover study. 2006 , 67, 321-33 | | 1 |
| 160 | Reducing cardiovascular risk in diabetes: beyond glycemic and blood pressure control. 2006 , 110, 137-45 | | 15 |
| 159 | Place des nouveaux traitements de l'ostéodystrophie rénale : divalés hydroxylés de la vitamine D « non hypercalcifiants », complexants non calciques, non magnésiens et non aluminiques des phosphates, et calcimimétiques. 2006 , 21, 9-32 | | |
| 158 | [Treatment of dyslipidemia: how and when to combine lipid lowering drugs]. 2006 , 50, 344-59 | | 8 |
| 157 | Achieving the therapeutic benefits of Niaspan [®] in daily practice. 2006 , 8, F68-F73 | | 3 |

| | | | |
|-----|--|---|-----|
| 156 | Clinical evidence for use of acetyl salicylic acid in control of flushing related to nicotinic acid treatment. 2006 , 60, 707-15 | | 39 |
| 155 | How safe is aggressive statin therapy?. 2006 , 21, 140-5 | | 9 |
| 154 | Reappraisal of 2003 NKF-K/DOQI guidelines for management of hyperparathyroidism in chronic kidney disease patients. 2006 , 2, 326-36 | | 12 |
| 153 | Dissolution profiles of nonprescription extended-release niacin and inositol niacinate products. 2006 , 63, 2128-34 | | 8 |
| 152 | Oral cholesteryl ester transfer protein (CETP) inhibitors: a potential new approach for treating coronary artery disease. 2006 , 49, 1-22 | | 113 |
| 151 | Drug Insight: renal indications of calcimimetics. 2006 , 2, 316-25 | | 9 |
| 150 | HDL elevation and lipid lowering therapy: current scenario and future perspectives. 2007 , 2, 214-27 | | 6 |
| 149 | Hypertriglyceridemia and cardiovascular risk reduction. 2007 , 29, 763-777 | | 97 |
| 148 | The safety of statins in clinical practice. 2007 , 370, 1781-90 | | 593 |
| 147 | Lipid-lowering agents that cause drug-induced hepatotoxicity. 2007 , 11, 597-613, vii | | 110 |
| 146 | Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study. 2007 , 3, 467-79 | | 14 |
| 145 | Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1. 2007 , 81, 849-57 | | 126 |
| 144 | Correction of low HDL cholesterol to reduce cardiovascular risk: practical considerations relating to the therapeutic use of prolonged-release nicotinic acid (Niaspan). 2007 , 61, 1914-21 | | 7 |
| 143 | Use of niacin in the prevention and management of hyperlipidemia. 2001 , 16, 14-20 | | 4 |
| 142 | Atherosclerosis regression. 2008 , 10, 187-94 | | 1 |
| 141 | Review article: The use of potentially hepatotoxic drugs in patients with liver disease. 2008 , 28, 1021-41 | | 67 |
| 140 | Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. <i>American Journal of Cardiology</i> , 2008 , 101, 625-30 | 3 | 152 |
| 139 | Niacin use and cutaneous flushing: mechanisms and strategies for prevention. <i>American Journal of Cardiology</i> , 2008 , 101, 14B-19B | 3 | 63 |

| | | | |
|-----|--|---|-----|
| 138 | Niacin and lipoprotein(a): facts, uncertainties, and clinical considerations. <i>American Journal of Cardiology</i> , 2008 , 101, 44B-47B | 3 | 34 |
| 137 | [Use of prolonged-release nicotinic acid in patients treated with statins as a secondary prevention and a persistently low HDL-cholesterol level in France]. 2008 , 57, 121-6 | | |
| 136 | Niaspan treatment improves neurological functional recovery in experimental autoimmune encephalomyelitis mice. 2008 , 32, 273-80 | | 16 |
| 135 | Increased total and high-molecular weight adiponectin after extended-release niacin. 2008 , 57, 404-9 | | 27 |
| 134 | HDL-C in post-menopausal women: An important therapeutic target. 2008 , 124, 275-82 | | 16 |
| 133 | Niacin for stroke prevention: evidence and rationale. 2008 , 14, 287-94 | | 6 |
| 132 | Effects of niacin on glucose control in patients with dyslipidemia. 2008 , 83, 470-8 | | 83 |
| 131 | Effect of omega-3-acid ethyl esters on the steady-state plasma pharmacokinetics of rosuvastatin in healthy adults. 2008 , 9, 2947-53 | | 15 |
| 130 | Effect of omega-3-acid ethyl esters on steady-state plasma pharmacokinetics of atorvastatin in healthy adults. 2008 , 9, 2939-45 | | 16 |
| 129 | Advances in the management of hyperlipidemia-induced atherosclerosis. 2008 , 6, 369-83 | | 16 |
| 128 | Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins. 2008 , 28, 1672-8 | | 125 |
| 127 | Dosage, titration, and gaps in treatment with extended release niacin in clinical practice. 2008 , 24, 1817-21 | | 16 |
| 126 | Fixed-dose combination of extended-release niacin plus simvastatin for lipid disorders. 2008 , 6, 1303-10 | | 3 |
| 125 | Use of extended-release niacin in clinical practice. 2008 , 3, 9-16 | | 1 |
| 124 | Pharmacologic management of isolated low high-density lipoprotein syndrome. 2008 , 15, 377-88 | | 13 |
| 123 | Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes. 2008 , 51, 331-51 | | 31 |
| 122 | Therapies to increase high-density lipoprotein cholesterol and their effect on cardiovascular outcomes and regression of atherosclerosis. 2008 , 336, 64-8 | | 8 |
| 121 | Nicotinic Acid. 2009 , 298-314 | | 4 |

| | | | |
|-----|--|----|---|
| 120 | Review of extended-release niacin/laropirant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia. 2009 , 5, 901-8 | 18 | |
| 119 | Laropirant in combination with extended-release niacin does not alter urine 11-dehydrothromboxane B2, a marker of in vivo platelet function, in healthy, hypercholesterolemic, and diabetic subjects. 2009 , 49, 1426-35 | 13 | |
| 118 | Mechanisms of flushing due to niacin and abolition of these effects. 2009 , 11, 685-9 | 17 | |
| 117 | Blood pressure-lowering effects of extended-release niacin alone and extended-release niacin/laropirant combination: a post hoc analysis of a 24-week, placebo-controlled trial in dyslipidemic patients. 2009 , 31, 115-22 | 28 | |
| 116 | Patients' experiences of niacin-induced flushing in clinical practice: a structured telephone interview. 2009 , 31, 130-40 | 19 | |
| 115 | The mechanism and mitigation of niacin-induced flushing. 2009 , 63, 1369-77 | 91 | |
| 114 | Flushing and other dermatologic adverse events associated with extended-release niacin therapy. 2009 , 3, 101-8 | 10 | |
| 113 | Flushing ASsessment Tool (FAST): psychometric properties of a new measure assessing flushing symptoms and clinical impact of niacin therapy. 2009 , 29, 215-29 | 14 | |
| 112 | Effects of aspirin when added to the prostaglandin D2 receptor antagonist laropirant on niacin-induced flushing symptoms. 2009 , 49, 416-22 | 16 | |
| 111 | Effects of extended-release niacin on lipid profile and adipocyte biology in patients with impaired glucose tolerance. 2009 , 205, 207-13 | 35 | |
| 110 | A review of lipid management in primary and secondary prevention. 2009 , 29, 2-12 | 41 | |
| 109 | What's the deal with niacin development: is laropirant add-on therapy a winning strategy to beat a straight flush?. 2009 , 20, 467-76 | 28 | |
| 108 | Niacin, an old drug with new perspectives for the management of dyslipidaemia. 2010 , 65, 23-8 | 2 | |
| 107 | High-density lipoprotein therapy: is there hope?. 2010 , 12, 315-28 | 8 | |
| 106 | Binder blinders-niacin of omission?. 2010 , 55, 628-30 | 11 | |
| 105 | All research does not a guideline make!. 2010 , 55, 631-4 | 2 | |
| 104 | Linguistic analysis of in-office dialogue among cardiologists, primary care physicians, and patients with mixed dyslipidemia. <i>American Journal of Cardiology</i> , 2010 , 106, 51-5 | 3 | 3 |
| 103 | Critical appraisal of laropirant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia. 2010 , 6, 183-90 | 6 | |

| | | |
|-----|--|-----|
| 102 | Safety and efficacy of laropirant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia. 2010 , 2, 61-71 | 4 |
| 101 | Low high-density lipoprotein cholesterol: current status and future strategies for management. 2010 , 6, 979-96 | 20 |
| 100 | Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial. 2010 , 5, 582-9 | 39 |
| 99 | Responses of blood lipids and lipoproteins to extended-release niacin and exercise in sedentary postmenopausal women. 2010 , 65, 924-32 | 4 |
| 98 | Niacin: from mechanisms of action to therapeutic uses. 2010 , 10, 204-17 | 31 |
| 97 | A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention. 2010 , 85, 365-79 | 35 |
| 96 | High-density lipoprotein and coronary heart disease: current and future therapies. 2010 , 55, 1283-99 | 155 |
| 95 | Nutrition and the deleterious side effects of nutritional supplements. 2010 , 28, 371-9 | 18 |
| 94 | Utilization patterns of extended-release niacin in Canada: analysis of an administrative claims database. 2010 , 26, e229-35 | 10 |
| 93 | Hepatotoxicity associated with metformin therapy in treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease. 2010 , 44, 1655-9 | 32 |
| 92 | Niacin extended release (Niaspan [®]): a guide to its use in lipid regulation. 2010 , 26, 1-5 | |
| 91 | Niacin extended-release therapy in phase III clinical trials is associated with relatively low rates of drug discontinuation due to flushing and treatment-related adverse events: a pooled analysis. 2011 , 11, 179-87 | 5 |
| 90 | International Union of Basic and Clinical Pharmacology. LXXXII: Nomenclature and Classification of Hydroxy-carboxylic Acid Receptors (GPR81, GPR109A, and GPR109B). 2011 , 63, 269-90 | 126 |
| 89 | Extended-release niacin/laropirant lowers serum phosphorus concentrations in patients with type 2 diabetes. 2011 , 5, 281-7 | 8 |
| 88 | Safety, tolerance, and efficacy of extended-release niacin monotherapy for treating dyslipidemia risks in persons with chronic tetraplegia: a randomized multicenter controlled trial. 2011 , 92, 399-410 | 27 |
| 87 | Biological roles and therapeutic potential of hydroxy-carboxylic Acid receptors. 2011 , 2, 51 | 23 |
| 86 | Effect of rosiglitazone on HDL metabolism in subjects with metabolic syndrome and low HDL. 2011 , 52, 136-42 | 10 |
| 85 | The role of high-density lipoproteins in reducing the risk of vascular diseases, neurodegenerative disorders, and cancer. 2011 , 2011, 496925 | 48 |

| | | |
|----|--|-----|
| 84 | Extended release niacin-laropiprant in patients with hypercholesterolemia or mixed dyslipidemias improves clinical parameters. 2011 , 5, 85-101 | 6 |
| 83 | Pharmacokinetics and dose recommendations of Niaspan [®] in chronic kidney disease and dialysis patients. 2011 , 26, 276-82 | 11 |
| 82 | The Facts behind niacin. 2011 , 5, 227-40 | 16 |
| 81 | Niacin inhibits vascular inflammation via the induction of heme oxygenase-1. 2012 , 125, 150-8 | 60 |
| 80 | Lipoprotein(a): more interesting than ever after 50 years. 2012 , 23, 133-40 | 89 |
| 79 | Anti-inflammatory effects of nicotinic acid in human monocytes are mediated by GPR109A dependent mechanisms. 2012 , 32, 669-76 | 139 |
| 78 | Safety and tolerability of extended-release niacin with laropiprant. 2012 , 11, 151-9 | 5 |
| 77 | Differential vasodilatory responses to local heating in facial, glabrous and hairy skin. 2012 , 32, 361-6 | 14 |
| 76 | Treatment options for the management of hypertriglyceridemia: strategies based on the best-available evidence. 2012 , 6, 413-26 | 68 |
| 75 | Extended-release niacin with laropiprant : a review on efficacy, clinical effectiveness and safety. 2012 , 13, 1345-62 | 24 |
| 74 | Lipids as New Targets. 2012 , 279-308 | |
| 73 | Relationship between Changes in Plasma Adiponectin Concentration and Insulin Sensitivity after Niacin Therapy. 2012 , 2, 211-217 | 10 |
| 72 | Attenuation of niacin-induced prostaglandin D(2) generation by omega-3 fatty acids in THP-1 macrophages and Langerhans dendritic cells. 2012 , 5, 37-50 | 5 |
| 71 | Nicotinic acid: clinical considerations. 2012 , 11, 551-64 | 13 |
| 70 | Challenges of a mechanistic feedback model describing nicotinic acid-induced changes in non-esterified fatty acids in rats. 2013 , 40, 497-512 | 7 |
| 69 | The high-fat high-fructose hamster as an animal model for niacin [®] biological activities in humans. 2013 , 62, 1840-9 | 5 |
| 68 | Update on marine omega-3 fatty acids: management of dyslipidemia and current omega-3 treatment options. 2013 , 230, 381-9 | 52 |
| 67 | Feedback modeling of non-esterified fatty acids in obese Zucker rats after nicotinic acid infusions. 2013 , 40, 623-38 | 13 |

| | | |
|----|---|-----|
| 66 | Lipoprotein(a), cardiovascular disease, and contemporary management. 2013 , 88, 1294-311 | 74 |
| 65 | The molecular basis for the immunomodulatory activities of unconjugated bilirubin. 2013 , 45, 2843-51 | 78 |
| 64 | Effects of low-dose niacin on dyslipidemia and serum phosphorus in patients with chronic kidney disease. 2013 , 32, 21-6 | 10 |
| 63 | Effect of colestevlam and niacin on low-density lipoprotein cholesterol and glycemic control in subjects with dyslipidemia and impaired fasting glucose. 2013 , 7, 423-32 | 8 |
| 62 | Genetic associations with valvular calcification and aortic stenosis. 2013 , 368, 503-12 | 556 |
| 61 | Adherence, Persistence, and Predictors Associated with Early Niacin Termination. 2013 , 29, 178-185 | 2 |
| 60 | Niacin increased glucose, insulin, and C-peptide levels in sedentary nondiabetic postmenopausal women. 2014 , 6, 913-20 | 13 |
| 59 | New therapies for reducing low-density lipoprotein cholesterol. 2014 , 43, 1007-33 | 31 |
| 58 | Effect of niacin on endothelial function: a systematic review and meta-analysis of randomized controlled trials. 2014 , 19, 54-66 | 18 |
| 57 | Dietary modulators of statin efficacy in cardiovascular disease and cognition. 2014 , 38, 1-53 | 9 |
| 56 | Lipid lowering in liver and chronic kidney disease. 2014 , 28, 339-52 | 7 |
| 55 | Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. 2015 , 36, 1012-22 | 770 |
| 54 | Immediate release niacin effect at stratified lipid levels. 2015 , 9, 48-53 | |
| 53 | Paraoxonase responses to exercise and niacin therapy in men with metabolic syndrome. 2015 , 20, 42-8 | 10 |
| 52 | Targeting lipoprotein (a): an evolving therapeutic landscape. 2015 , 17, 502 | 7 |
| 51 | Prescription omega-3 fatty acid products: considerations for patients with diabetes mellitus. 2016 , 9, 109-18 | 10 |
| 50 | Future Directions to Establish Lipoprotein(a) as a Treatment for Atherosclerotic Cardiovascular Disease. 2016 , 30, 101-8 | 21 |
| 49 | Nicotinic acid and derivatives. 2016 , 157-162 | |

| | | |
|----|---|----|
| 48 | Emerging Therapeutic Options for Lowering of Lipoprotein(a): Implications for Prevention of Cardiovascular Disease. 2016 , 18, 69 | 9 |
| 47 | Expert opinion: the therapeutic challenges faced by statin intolerance. 2016 , 17, 1497-507 | 40 |
| 46 | Measuring niacin-associated skin toxicity (NASTy) stigmata along with symptoms to aid development of niacin mimetics. 2017 , 58, 783-797 | 5 |
| 45 | Vitamin C down-regulate apo(a) expression via Tet2-dependent DNA demethylation in HepG2 cells. 2017 , 98, 637-645 | 21 |
| 44 | Randomized controlled trial of different aspirin regimens for reduction of niacin-induced flushing. 2017 , 74, 898-903 | 2 |
| 43 | Lipoprotein(a) Levels and Recurrent Vascular Events After First Ischemic Stroke. 2017 , 48, 36-42 | 12 |
| 42 | Diallyl disulphide inhibits apolipoprotein(a) expression in HepG2 cells through the MEK1-ERK1/2-ELK-1 pathway. 2017 , 16, 223 | 5 |
| 41 | Lipoprotein(a) in clinical practice: New perspectives from basic and translational science. 2018 , 55, 33-54 | 15 |
| 40 | Coronary Artery Disease. 2018 , 253-263.e2 | |
| 39 | Niacin-Induced Anicteric Microvesicular Steatotic Acute Liver Failure. 2018 , 2, 1293-1298 | 8 |
| 38 | NAD metabolism as a target for metabolic health: have we found the silver bullet?. 2019 , 62, 888-899 | 33 |
| 37 | Dietary natural products as emerging lipoprotein(a)-lowering agents. 2019 , 234, 12581-12594 | 17 |
| 36 | Fibrate and Niacin. 2021 , 103-110 | |
| 35 | Lipoprotein (a): When to Measure and How to Treat?. 2021 , 23, 51 | 2 |
| 34 | Management of Hypertriglyceridemia. 2007 , 201-220 | 3 |
| 33 | Treatment of patients with lipid disorders in the primary care setting: new treatment guidelines and their implications. 2003 , 96, 266-75 | 5 |
| 32 | New frontiers in the treatment of diabetic dyslipidemia. 2013 , 10, 204-12 | 4 |
| 31 | Nicotinic acid: a lipid-lowering agent with unrealized potential. 2014 , 26, 1-5 | 1 |

- 30 Nicotinic acid: Do we know how it works after 55 years of clinical experience. **2012**, 1, 50 1
- 29 References. **2002**, 106, 3373-3421 1
- 28 Antihyperlipidemic Agents. **2003**, 339-383
- 27 Nicotinic acid and derivatives. **2006**, 2512-2516
- 26 Eine graue Liste. **2006**, 27,
- 25 Effects of Nutrient Supplements and Nutraceuticals on Risk for Cardiovascular Disease. **2006**, 79-146
- 24 Triglycerides and Risk for Atherosclerotic Disease. **2006**, 341-388
- 23 Management of Elevated Low-Density Lipoprotein Cholesterol. **2006**, 255-294
- 22 Stroke Prevention. **2006**, 545-584
- 21 Pharmacological Therapy for Cardiovascular Disease. **2007**, 121-148
- 20 Pharmacologic Therapy for Hypertriglyceridemia and Low HDL: Rationale for Combination Therapy. **2007**, 515-527
- 19 Effects of Nutrient Supplements and Nutraceuticals on Risk for Cardiovascular Disease. **2007**, 79-145
- 18 Retinal Toxicity of Systemic Medications. **2008**, 2213-2224
- 17 LIPID REGULATING DRUGS. **2009**, 527-570
- 16 ENDOCRINE AND METABOLIC ADVERSE EFFECTS OF NON-HORMONAL AND NON-METABOLIC DRUGS. **2009**, 571-691
- 15 Effects of Niacin on HDL Metabolism. **2010**, 145-149
- 14 Hyperlipidemia medication management in patients admitted for a myocardial infarction. **2011**, 9, 31-6
- 13 Coronary Artery Disease. **2012**, 227-236.e2

| | | | |
|----|--|-----|----|
| 12 | How Lipid-Lowering Agents Work: The Good, the Bad, and the Ugly. 2014 , 45-65 | | |
| 11 | Non-Statin Treatment of Dyslipidemia. 2015 , 201-231 | | |
| 10 | Pharmakotherapie und Medikamente. 2017 , 325-337 | | |
| 9 | Medicines. 2017 , 371-384 | | |
| 8 | Drug Induced Maculopathies. 2020 , 1-23 | | |
| 7 | Pilot study on the safety and tolerability of extended release niacin for HIV-infected patients with hypertriglyceridemia. <i>Hawaii Medical Journal</i> , 2010 , 69, 122-5 | | 3 |
| 6 | The effects of extended release niacin on lipoprotein sub-particle concentrations in HIV-infected patients. <i>Hawai'i Journal of Medicine & Public Health: A Journal of Asia Pacific Medicine & Public Health</i> , 2013 , 72, 123-7 | 0.6 | 1 |
| 5 | Pharmacological measures to increase HDL-C among high risk isolated low HDL cases: a randomized study amongst north Indians. <i>Indian Journal of Medical Research</i> , 2013 , 138, 873-81 | 2.9 | 1 |
| 4 | Ocular Effects of Niacin: A Review of the Literature. <i>Medical Hypothesis, Discovery, and Innovation in Ophthalmology</i> , 2015 , 4, 64-71 | 1.4 | 12 |
| 3 | Drug Induced Maculopathies. 2022 , 3739-3761 | | |
| 2 | Drug Induced Maculopathies. 2022 , 1-23 | | 0 |
| 1 | NAD+ Metabolism and Interventions in Premature Renal Aging and Chronic Kidney Disease. 2023 , 12, 21 | | 0 |